Suzhou Bioway Biotechnology

Suzhou Bioway Biotechnology is a clinical-stage biotechnology company headquartered in the Suzhou Industrial Park, China, focused on the development of innovative CAR-T cell therapies. The company leverages its proprietary cell engineering platforms to create next-generation immunotherapies for both hematological malignancies and solid tumors. Its pipeline includes several high-potential candidates, such as bispecific CAR-T cells targeting CD19 and CD22, as well as therapies directed at BCMA and GPC3. Bioway aims to address the limitations of current cell therapies by enhancing persistence and efficacy in the immunosuppressive tumor microenvironment. The company has established integrated capabilities spanning from early-stage research to clinical development and GMP manufacturing.